CCGs will be ranked by 'innovation scorecards'

Friday 27 April 2012

innovation scorecardsClinical commissioning groups (CCGs) are to be ranked on the level of access they provide to National Institute for Health and Clinical Excellence (NICE)-approved drugs with the use of innovation scorecards.

The scorecards, which are due to be published later this year, will provide local data on the level of access patients have to NICE approved treatments.

The scorecards are part of a compliance programme, which is currently being developed by NICE and the pharmaceutical industry, and enforces strict guidelines over local formularies. The Department of Health (DH) announced in its Innovation, health and wealth report, published in December 2011, that CCGs are expected to provide access to new treatments within 90 days of approval.

It is hoped the innovation scorecards will reduce postcode lotteries in the provision of care but GP commissioning leaders have warned it will create a conflict of interest if drug companies are involved in developing guidance for CCGs.

Chair of the NHS Alliance, Dr Michael Dixon, said: 'The danger is that we end up with CCGs ranked on how they carry out NICE, and that becomes a new target in itself, and we ratchet up demand in areas where CCGs have decided not to follow NICE.

'NICE is very important and useful, but it is not local and it doesn't always have a primary care focus. We need to allow for the different flavours in different populations.'

A spokesperson for the DH said that the scorecards will be used to track adoption of NICE technology appraisals at local level. He said: 'We have already begun work with the NHS and industry to assess and explore the different experiences of local formularies, what additional support may be required and to identify and spread best practice.'


Further information

Website: National Institute for Health and Clinical Excellence

Website: Department of Health

Department of Health website: Innovation, health and wealthThe government directive, published in December 2011, states that clinically appropriate appraisals must be automatically included in formularies.

Wellards News, February 2012:NICE to produce best practice guide on creating local formularies
The drugs watchdog is to produce a best practice guide for NHS trusts on how to incorporate technology appraisals into local formularies.

Your page is loading. Please wait...